EpiCypher is a bioscience company developing unique reagents and services for chromatin biology and epigenetics research.

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. Our technologies and products are making studies possible that were not imaginable just a few years ago. Our innovation is a direct result of the scientific power associated with EpiCypher. Our renowned chromatin researchers possess expertise and unique insight into epigenetics that benefit our customers in ways other companies cannot.

Arising from an abundance of demand for high quality products from the laboratories of Mark Bedford, Brian Strahl, and Or Gozani EpiCypher was founded on January 18, 2012 as a spin-out from University of North Carolina at Chapel Hill. Starting with the groundbreaking and proprietary histone peptide array platform, EpiGold™, EpiCypher has developed a wide portfolio of best in class products. EpiCypher's mission is to develop products to enable researchers to complete experiments that are not otherwise possible.